# Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis

> **NCT07235644** · — · ACTIVE_NOT_RECRUITING · sponsor: **Uppsala University** · enrollment: 184 (estimated)

## Conditions studied

- MS (Multiple Sclerosis)
- Multiple Sclerosis (MS) - Relapsing-remitting
- Multiple Sclerosis (Relapsing Remitting)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07235644
- **Lead sponsor:** Uppsala University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07235644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07235644, "Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07235644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*